Abstract 1581P
Background
Surgery with perioperative chemotherapy has been standard of care in patients with locally advanced gastric and gastroesophageal junction (GEJ) cancer since FLOT4-AIO trial. However, less than half of patients complete all adjuvant cycles. We studied total neoadjuvant chemotherapy with FOLFIRINOX regimen followed by surgery in this setting.
Methods
We conducted non-randomized, open-label, single-center phase II study in 119 patients with locally advanced resectable gastric and GEJ cancer. Sixty patients were enrolled to received 8 cycles of FOLFIRINOX preoperatively. This prospective cohort was compared to the retrospective cohort (n = 59), that received standard perioperative FLOT regimen (4 cycles before and 4 cycles after surgery). The primary endpoint was disease-free survival (DFS). Secondary endpoints were safety profile and pathological complete response rate (pCR).
Results
In the FOLFIRINOX and FLOT groups 78,6% and 77,8% of patients completed all planned cycles and underwent surgery, respectively. Dose reductions and drug withdrawal rates were higher in the FLOT group. More patients achieved pCR and near-pCR in the FLOT group by three different tumor regression grading systems (TRG 1a/b by Becker, 1/2 by Mandart, and 3/4 by Lavnikova): 47,7%, 40,5%, and 35,7% in the FLOT group and 25%, 27,3%, and 29,6% in the FOLFIRINOX group, respectively, though statistically insignificant. pCR or partial pathological response by any of TRG systems did not predict one-year DFS regardless of the treatment regimen. One-year DFS was numerically higher in the FOLFIRINOX group - 90,4% vs 67,5 % in the FLOT group (hazard ratio [HR] 0,65, 95% CI 0,29 – 1,45, p=0,29). The risk of recurrence in the FOLFIRINOX group was lower than in the FLOT group (odds ratio [OR] 0,40, 95% CI 0,16-0,97, p=0,047). Regional lymph node involvement (ypN2), lymphatic, vascular and perineural invasion negatively affected DFS (p=0,046; p=0,014; p=0,0021; p=0,04, respectively).
Conclusions
The total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with locally advanced gastric and GEJ cancer demonstrated comparable to the perioperative FLOT one-year DFS rate regardless of pCR and manageable safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22